WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Rafal Mahdi Hasan, Hadeel Abdulelah Karbel* and Alaa S. Alaawad

ABSTRACT

Background: Breast cancer is the most frequently diagnosed cancer and it is the leading cause of cancer death among females worldwide, with an estimated 2,261,419 new cases and 684,996deaths in 2020. Several recent studies have demonstrated that Stathmin1 expression may be closely associated with prognosis in patients with breast cancer. Stathmin1 (STMN1), also known as oncoprotein 18, is a cytosolic phosphoprotein and a key regulator of cell division due to its microtubule depolymerization in a phosphorylation-dependent manner. Aim of the study: evaluate the immunohistochemical expression of stathmin1 in patients with invasive breast carcinoma and its association with several prognostic factors. Patients and Methods: In this study, we used formalin-fixed paraffin-embedded tissue blocks from 50 patients of invasive breast carcinoma including different grades and types. Histological sections were taken for hematoxyline and eosin staining to assess histopathological features. Monoclonal antibody for STMN1 was used for immunohistochemical staining of tissue sections and STMN1 expression was semi quantitatively scored. The Association between clinicopathological parameters and stathmin1 expression was done. Results: Fifty cases of invasive breast carcinoma were studied, 32 cases (64%) show high expression and 18 cases (36%) show low expression. Significant association with tumor grade, ER hormonal negativity, lympho-vascular invasion and triple negative breast carcinoma (TNBC), and no significant association was found with tumor histological type, IHC based subtype, PR hormonal status and HER-2 status. Conclusions: STMN1 according to this study prove to be a powerful marker in predicting the prognosis of breast carcinoma. With further work up and more extensive studies it may be of routine use in the near future.

[Full Text Article] [Download Certificate]